State Street Health Care Select Sector SPDR ETF
XLVDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 24, 2025 | $0.66 | 2025-12-22 | 2025-12-22 |
| September 24, 2025 | $0.62 | 2025-09-22 | 2025-09-22 |
| June 25, 2025 | $0.63 | 2025-06-23 | 2025-06-23 |
| March 26, 2025 | $0.56 | 2025-03-24 | 2025-03-24 |
| December 26, 2024 | $0.62 | 2024-12-23 | 2024-12-23 |
Dividends Summary
- Consistent Payer: State Street Health Care Select Sector SPDR ETF has rewarded shareholders with 77 dividend payments over the past 18 years.
- Total Returned Value: Investors who held XLV shares during this period received a total of $24.97 per share in dividend income.
- Latest Payout: The most recent dividend of $0.66/share was paid 30 days ago, on December 24, 2025.
- Yield & Schedule: XLV currently pays dividends quarterly with an annual yield of 1.56%.
- Dividend Growth: Since 2007, the dividend payout has grown by 428.1%, from $0.12 to $0.66.
Company News
Wall Street experienced a sector rotation with investors shifting towards small caps and healthcare stocks, while AI-related tech stocks like Nvidia and AMD experienced significant declines amid market repositioning.
The healthcare sector is experiencing significant growth, with pharmaceutical companies like Eli Lilly and Novo Nordisk leading the way. Driven by strong quarterly results, drug pricing negotiations, and investor flight to safety, the sector has outperformed the S&P 500 by over seven times in the past month.
CVS Health has experienced a significant stock rally in 2025, rising 75% after a challenging 2024. The company's new CEO David Joyner has improved financial performance, with better-than-expected Q3 earnings and revenue, making the stock appear attractively valued.
Pfizer's stock has been struggling, trading at low levels with a 30% decline over five years. Despite low valuation and upcoming Q3 earnings report, investors remain cautious about the company's growth potential and future prospects.
Intuitive Surgical is positioned for potential growth with recent FDA approvals and European market expansion, attracting congressional investor interest ahead of its Q3 2025 earnings report.
